Literature DB >> 9356479

The prion model for [URE3] of yeast: spontaneous generation and requirements for propagation.

D C Masison1, M L Maddelein, R B Wickner.   

Abstract

The genetic properties of the non-Mendelian element, [URE3], suggest that it is a prion (infectious protein) form of Ure2p, a mediator of nitrogen regulation in Saccharomyces cerevisiae. Into a ure2Delta strain (necessarily lacking [URE3]), we introduced a plasmid overproducing Ure2p. This induced the frequent "spontaneous generation" of [URE3], with properties identical to the original [URE3]. Altering the translational frame only in the prion-inducing domain of URE2 shows that it is Ure2 protein (and not URE2 RNA) that induces appearance of [URE3]. The proteinase K-resistance of Ure2p is unique to [URE3] strains and is not seen in nitrogen regulation of normal strains. The prion-inducing domain of Ure2p (residues 1-65) can propagate [URE3] in the absence of the C-terminal part of the molecule. In contrast, the C-terminal part of Ure2p cannot be converted to the prion (inactive) form without the prion-inducing domain covalently attached. These experiments support the prion model for [URE3] and extend our understanding of its propagation.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9356479      PMCID: PMC25018          DOI: 10.1073/pnas.94.23.12503

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  25 in total

Review 1.  Interrelationships of the pathways of mRNA decay and translation in eukaryotic cells.

Authors:  A Jacobson; S W Peltz
Journal:  Annu Rev Biochem       Date:  1996       Impact factor: 23.643

2.  Ureidosuccinic acid uptake in yeast and some aspects of its regulation.

Authors:  R Drillien; F Lacroute
Journal:  J Bacteriol       Date:  1972-01       Impact factor: 3.490

3.  Transcriptional regulation of the DAL5 gene in Saccharomyces cerevisiae.

Authors:  R Rai; F Genbauffe; H Z Lea; T G Cooper
Journal:  J Bacteriol       Date:  1987-08       Impact factor: 3.490

4.  Role of the chaperone protein Hsp104 in propagation of the yeast prion-like factor [psi+].

Authors:  Y O Chernoff; S L Lindquist; B Ono; S G Inge-Vechtomov; S W Liebman
Journal:  Science       Date:  1995-05-12       Impact factor: 47.728

5.  Rapid and efficient site-specific mutagenesis without phenotypic selection.

Authors:  T A Kunkel
Journal:  Proc Natl Acad Sci U S A       Date:  1985-01       Impact factor: 11.205

6.  Transmission of the BSE agent to mice in the absence of detectable abnormal prion protein.

Authors:  C I Lasmézas; J P Deslys; O Robain; A Jaegly; V Beringue; J M Peyrin; J G Fournier; J J Hauw; J Rossier; D Dormont
Journal:  Science       Date:  1997-01-17       Impact factor: 47.728

7.  Non-Mendelian mutation allowing ureidosuccinic acid uptake in yeast.

Authors:  F Lacroute
Journal:  J Bacteriol       Date:  1971-05       Impact factor: 3.490

8.  Overexpression of active Syrian golden hamster prion protein PrPc as a glutathione S-transferase fusion in heterologous systems.

Authors:  S Weiss; M Famulok; F Edenhofer; Y H Wang; I M Jones; M Groschup; E L Winnacker
Journal:  J Virol       Date:  1995-08       Impact factor: 5.103

9.  Prion protein (PrP) with amino-proximal deletions restoring susceptibility of PrP knockout mice to scrapie.

Authors:  M Fischer; T Rülicke; A Raeber; A Sailer; M Moser; B Oesch; S Brandner; A Aguzzi; C Weissmann
Journal:  EMBO J       Date:  1996-03-15       Impact factor: 11.598

10.  Prion-inducing domain of yeast Ure2p and protease resistance of Ure2p in prion-containing cells.

Authors:  D C Masison; R B Wickner
Journal:  Science       Date:  1995-10-06       Impact factor: 47.728

View more
  74 in total

1.  Mutational analysis of the [Het-s] prion analog of Podospora anserina. A short N-terminal peptide allows prion propagation.

Authors:  V Coustou; C Deleu; S J Saupe; J Bégueret
Journal:  Genetics       Date:  1999-12       Impact factor: 4.562

2.  Gln3p nuclear localization and interaction with Ure2p in Saccharomyces cerevisiae.

Authors:  A A Kulkarni; A T Abul-Hamd; R Rai; H El Berry; T G Cooper
Journal:  J Biol Chem       Date:  2001-06-14       Impact factor: 5.157

3.  Two prion-inducing regions of Ure2p are nonoverlapping.

Authors:  M L Maddelein; R B Wickner
Journal:  Mol Cell Biol       Date:  1999-06       Impact factor: 4.272

4.  Mtt1 is a Upf1-like helicase that interacts with the translation termination factors and whose overexpression can modulate termination efficiency.

Authors:  K Czaplinski; N Majlesi; T Banerjee; S W Peltz
Journal:  RNA       Date:  2000-05       Impact factor: 4.942

5.  Amyloid of the Candida albicans Ure2p prion domain is infectious and has an in-register parallel β-sheet structure.

Authors:  Abbi Engel; Frank Shewmaker; Herman K Edskes; Fred Dyda; Reed B Wickner
Journal:  Biochemistry       Date:  2011-06-15       Impact factor: 3.162

6.  Progress toward an ultimate proof of the prion hypothesis.

Authors:  Susan W Liebman
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-01       Impact factor: 11.205

7.  Generation of prions in vitro and the protein-only hypothesis.

Authors:  Rodrigo Diaz-Espinoza; Claudio Soto
Journal:  Prion       Date:  2010-04-05       Impact factor: 3.931

Review 8.  Prion amyloid structure explains templating: how proteins can be genes.

Authors:  Reed B Wickner; Frank Shewmaker; Herman Edskes; Dmitry Kryndushkin; Julie Nemecek; Ryan McGlinchey; David Bateman; Chia-Lin Winchester
Journal:  FEMS Yeast Res       Date:  2010-12       Impact factor: 2.796

9.  The mechanisms of [URE3] prion elimination demonstrate that large aggregates of Ure2p are dead-end products.

Authors:  Leslie Ripaud; Laurent Maillet; Christophe Cullin
Journal:  EMBO J       Date:  2003-10-01       Impact factor: 11.598

10.  The [URE3] prion is an aggregated form of Ure2p that can be cured by overexpression of Ure2p fragments.

Authors:  H K Edskes; V T Gray; R B Wickner
Journal:  Proc Natl Acad Sci U S A       Date:  1999-02-16       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.